| HOME >> MEDICINE >> TECHNOLOGY |
* The additional blood pressure reductions provided by an aliskiren/valsartan combination over each antihypertensive agent alone are sustained over the entire 24-h dosing interval in both dippers and non-dippers and exhibit less variability.
Direct renin inhibition with aliskiren improves blood pressure control in obese patients with hypertension who do not respond to first-line hydrochlorothiazide treatment J Jordan, SW Boye, S Le Breton, DL Keefe; Poster 401
* The combination of aliskiren with hydrochlorothiazide provided significant additional blood pressure reductions and significantly improved blood pressure control rates in obese patients with hypertension, without the increased rate of edema associated with amlodipine/hydrochlorothiazide.
Aliskiren, a direct renin inhibitor, provides antihypertensive efficacy and excellent tolerability independent of age or gender in patients with hypertension B Dahlöf, DR Anderson, V Arora, C Bush, DL Keefe; Poster P-376
* This pooled analysis of randomized clinical trials in a total
of 8481 patients showed that once-daily treatment with the direct
renin inhibitor aliskiren at doses of 150 and 300 mg provided
effective, dose dependent blood pressure-lowering independent of
age or gender in patients with mild-to-moderate hypertension. *
Aliskiren treatment provided numerically greater placebo-subtracted
reductions in mean systolic blood pressure in patients aged over 65
years compared with younger patients. This may be clinically useful
because the prevalence of isolated systolic hypertension is
increased in elderly patients, and elevated systolic blood pressure
is difficult to control. * Aliskiren 150 and 300 mg monotherapy was
equally well tolerated in elderly and you
'"/>